Shivani Chib | Pharmacology, Toxicology and Pharmaceutical Science | Women Researcher Award

Published on by Forensic Scientist

Ms. Shivani Chib | Pharmacology, Toxicology and Pharmaceutical Science | Women Researcher Award

Central University of Punjab | India

Ms. Shivani Chib is an emerging researcher in the field of pharmacology, specializing in neurodegenerative diseases with a particular focus on Parkinson’s disease and the therapeutic potential of phytoconstituents. Currently pursuing her Ph.D. at the Central University of Punjab, Bathinda, she has contributed extensively through high-impact publications, innovative patents, international presentations, and active peer-reviewing for reputed journals. With multiple national and international awards, she stands out as a dedicated woman researcher committed to advancing pharmacological science and drug discovery.

Professional Profile

Scopus

Google Scholar

Education

Ms. Shivani Chib is currently pursuing her doctoral research in Pharmacology at the Central University of Punjab, Bathinda, under the guidance of Dr. Randhir Singh. Her Ph.D. research centers on Parkinson’s disease and the therapeutic potential of bioactive phytoconstituents, reflecting her dedication to translational research in neuropharmacology. Before her doctoral studies, she completed her Master of Pharmacy in Pharmacology from ISF College of Pharmacy, where she excelled academically and carried out research in experimental pharmacology. Her academic journey began with a Bachelor of Pharmacy in Pharmaceutical Sciences from Sri Sai College of Pharmacy. This progression in higher education reflects not only her intellectual growth but also her determination to specialize in pharmacology and contribute to the field of neuroscience.

Experience

Her professional journey as a researcher began during her postgraduate studies, where she worked as a Research Scholar and focused on understanding drug mechanisms and neuroprotective agents. Currently, as a Ph.D. Research Scholar at the Central University of Punjab, she is engaged in cutting-edge research on Parkinson’s disease, with particular emphasis on dopaminergic neuronal death and the role of phytochemicals such as luteolin and wogonin. She has also contributed as a reviewer for multiple Springer Nature journals, a role that reflects her expertise and recognition in the scientific community. Her active engagement in national and international conferences, combined with her innovative experimental approaches, illustrates her wide-ranging experience in both research and academic settings.

Research Interest

Her research interests revolve around neuropharmacology, neurodegenerative disorders, natural product-based drug discovery, and cognitive impairments associated with aging. She has a deep focus on elucidating the mechanisms of dopaminergic neuronal death in Parkinson’s disease and identifying bioactive phytoconstituents like luteolin and wogonin as potential therapeutic agents. Additionally, her work extends to exploring CNS toxicity of chemotherapeutics, marine functional foods, metabolic syndromes, and the cross-talk between central nervous and cardiovascular systems.

Awards and Recognitions

Ms. Shivani Chib has received numerous awards and recognitions throughout her career, including Best Working Model Award, Best Poster Awards at national and international conferences, and the prestigious GPAT fellowship. She has been awarded multiple international travel grants, including from the Movement Disorder Society and the Anusandhan National Research Foundation, enabling her to present her work globally, including at conferences in the USA and Japan. She has also received certificates of excellence in peer reviewing from Springer Nature and BP International. Her innovation in neuroscience is further highlighted by her registered patents on novel laboratory apparatuses, reflecting her inventive approach to experimental pharmacology.

Publications

Ms. Shivani Chib has published widely in reputed international journals, with her contributions cited in several scholarly works. Selected publications include:

Title: Unveiling the interplay of AMPK/SIRT1/PGC-1α axis in brain health: Promising targets against aging and NDDs
Journal: Ageing Research Reviews
Published on: 2024
Citation: 49

Title: Manganese and related neurotoxic pathways: A potential therapeutic target in neurodegenerative diseases
Journal: Neurotoxicology and Teratology
Published on: 2022
Citation: 35

Title: Unlocking the therapeutic potential of natural stilbene: exploring pterostilbene as a powerful ally against aging and cognitive decline
Journal: Ageing Research Reviews
Published on: 2023
Citation: 21

Title: Treatment of diabetic complications: do flavonoids holds the keys?
Journal: Critical Reviews in Food Science and Nutrition
Published on: 2024
Citation: 16

Title: Paradigms and success stories of natural products in drug discovery against neurodegenerative disorders (NDDs)
Journal: Current Neuropharmacology
Published on: 2024
Citation: 15

Title: Microbiota-brain-gut-Axis relevance to Parkinson’s disease: potential therapeutic effects of probiotics
Journal: Current Pharmaceutical Design
Published on: 2022
Citation: 11

Title: Role of flavonoids in mitigating the pathological complexities and treatment hurdles in Alzheimer’s disease
Journal: Phytotherapy Research
Published on: 2025
Citation: 10

Conclusion

Ms. Shivani Chib has established herself as a promising woman researcher in pharmacology through her strong academic background, impactful publications, innovative patents, and global recognitions. Her work in exploring the therapeutic applications of phytoconstituents against neurodegenerative disorders has the potential to open new pathways for safer and more effective treatments. With her commitment to excellence, interdisciplinary approach, and growing global presence, she exemplifies the qualities of a future leader in pharmacological sciences. She is therefore highly deserving of the Women Researcher Award, which would further empower her to continue contributing to scientific progress and global healthcare solutions.

Shanbo Ma | Pharmacology | Best Researcher Award

Published on by Forensic Scientist

Dr. Shanbo Ma | Pharmacology | Best Researcher Award

Deputy Chief Pharmacist | Xijing Hospital of Air Force Medical University | China

Shanbo Ma is a dedicated researcher in the field of Chinese pharmacology, focusing on the pharmacological mechanisms and therapeutic potential of traditional Chinese medicine (TCM). With a strong academic background and extensive research experience, he has contributed significantly to the study of anti-inflammatory effects and active ingredients in TCM. His expertise spans molecular biology, cell biology, and bioinformatics, making him a key figure in integrating computational and experimental approaches to drug discovery.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Strong Research Output & Impact 📚

    • Published multiple peer-reviewed articles in high-impact journals such as Frontiers in Pharmacology, Journal of Ethnopharmacology, and Journal of Biomolecular Structure & Dynamics.
    • Research spans diverse pharmacological applications, including colorectal cancer, anxiety treatment, ulcerative colitis, and depression, indicating a broad impact in Chinese pharmacology and molecular medicine.
    • Co-first and co-corresponding authorships in multiple papers highlight leadership in research projects.

  • Interdisciplinary Expertise 🔬

    • Skilled in network pharmacology, molecular docking, bioinformatics, and experimental validation, demonstrating a strong foundation in both computational and experimental pharmacology.
    • Expertise in cell biology, molecular biology, and animal experiments, which are critical for translational research in pharmacology.

  • Technical & Analytical Proficiency 💻

    • Proficient in essential research tools, including GraphPad, Cytoscape, Photoshop, SYBYL, and Image J, supporting advanced data analysis and visualization.

  • Recognition & Awards 🏆

    • Received the Outstanding Paper Award (2023) from the Chinese Pharmaceutical Society, a significant achievement showcasing research excellence.

  • Educational Background & Training 🎓

    • Holds a Ph.D. in Science of Chinese Pharmacology from Northwest University (2020–2024).
    • Completed a Master’s in Chinese Medicine from Shaanxi University of Chinese Medicine and a Bachelor’s in Pharmacology from Bengbu Medical University, providing a solid academic foundation.

🎓 Education

  • 📌 2020.09 – 2024.06 | Northwest University | Doctorate in Science of Chinese Pharmacology
  • 📌 2014.09 – 2017.07 | Shaanxi University of Chinese Medicine | Master’s in Chinese Medicine
  • 📌 2013.09 – 2017.07 | Bengbu Medical University | Bachelor’s in Pharmacology

💼 Experience

Shanbo Ma has been actively involved in pharmacological research, specializing in the bioactivity screening and mechanistic exploration of TCM. His work integrates network pharmacology, bioinformatics, and molecular docking techniques to elucidate drug mechanisms. He has also demonstrated proficiency in project design and team coordination, leading multiple research initiatives and collaborations.

🔬 Research Interests On Pharmacology

  •  Screening the pharmacological substance basis of traditional Chinese medicine
  •  Investigating the anti-inflammatory effects and mechanisms of TCM and its active ingredients
  •  Utilizing bioinformatics and network pharmacology to analyze drug-target interactions
  •  Exploring molecular docking and experimental validation methods for TCM efficacy

🏆 Awards

  • 🏅 Outstanding Paper Award, Chinese Pharmaceutical Society (2023)

📚 Publications

  • Elucidation of the mechanism of action of ailanthone in the treatment of colorectal cancer: integration of network pharmacology, bioinformatics analysis and experimental validation

    • Authors: Ma Shanbo, Guo Xiaodi, et al.
    • Publication Year: 2024

  • Glycyrrhizic acid treatment ameliorates anxiety-like behaviour via GLT1 and Per1/2-dependent pathways

    • Authors: Ma Shanbo, Chong Ye, et al.
    • Publication Year: 2024

  • Virtual screening-molecular docking-activity evaluation of Ailanthus altissima (Mill.) swingle bark in the treatment of ulcerative colitis

    • Authors: Ma Shanbo, Liu Lun, et al.
    • Publication Year: 2023

  • Investigating the mechanism of Sinisan formula in depression treatment: a comprehensive analysis using GEO datasets, network pharmacology, and molecular docking

    • Authors: Zheng Meiling, Yang, Shi Xiaopeng#, Ma Shanbo#
    • Publication Year: 2024

  • Network pharmacology and molecular docking to study the potential molecular mechanism of Qi Fu Yin for diabetic encephalopathy

    • Authors: Guo Xiaodi, Wang Feiyan, Ma Shanbo#, Shi Xiaopeng#
    • Publication Year: 2023

  • Investigation into the in vivo mechanism of diosmetin in patients with breast cancer and COVID-19 using bioinformatics

    • Authors: Wang Jin*, Ma Shanbo*, et al.
    • Publication Year: 2022

🔬 Skills

  •  Expertise in cell biology, molecular biology, and animal experiments
  •  Proficient in bioinformatics tools such as GraphPad, AI, Photoshop, ImageJ, Cytoscape, and SYBYL
  •  Strong ability to design projects independently and coordinate teamwork

🔚 Conclusion

Shanbo Ma is a passionate and accomplished researcher in Chinese pharmacology, making substantial contributions to understanding the therapeutic mechanisms of traditional medicines. His expertise in network pharmacology, molecular docking, and bioinformatics enhances his ability to uncover novel insights in drug discovery. With numerous publications and an award-winning research portfolio, he continues to drive advancements in the field of traditional medicine research.

Mei-Lang Kung | Pharmacology | Women Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Mei-Lang Kung | Pharmacology | Women Researcher Award

Senior Assistant Research Fellow | Kaohsiung Veterans General Hospital | Taiwan

Dr. Mei-Lang Kung is a distinguished researcher and academic specializing in cancer biology, gene engineering, and phytochemical pharmacology. She currently serves as a Senior Assistant Research Fellow at the Department of Medical Education and Research, Kaohsiung Veterans General Hospital, and an Assistant Professor at Shu-Zen Junior College of Medicine and Management. With a strong background in molecular biology and nanomedicine, Dr. Kung has contributed significantly to innovative research in oncology and nanomaterials for medical applications.

Profile👤

ORCID

Scopus

Strengths for the Awards✨

  • Strong Academic Background 📚

    • Dr. Mei-Lang Kung holds a Ph.D. in Biological Science from National Sun Yat-sen University (2012).
    • Her dissertation focused on cancer cell migration and epithelial-mesenchymal transition, a highly relevant area in biomedical research.

  • Extensive Research Expertise 🔬

    • Her work spans multiple interdisciplinary fields, including cancer biology, gene engineering, phytochemical pharmacology, and green nanomaterials.
    • These diverse skill sets enhance the impact of her research in translational medicine.

  • Significant Research Contributions 🏆

    • 21+ peer-reviewed publications in high-impact journals (SCI-indexed).
    • Notable research on nanomedicine and cancer treatment strategies, contributing to innovative therapeutic approaches.
    • Demonstrated leadership as a corresponding author in multiple studies, reflecting independent research capability.

  • Recognition & Awards 🥇

    • Best Poster Award (2021) from the Taiwan Urology Association.
    • National Taiwan University System Young Scholars Award (2018) for innovative research.
    • Multiple Outstanding Paper Awards at prestigious conferences (IEEE, New Advance in Medicine, etc.).
    • These accolades highlight her excellence in research and scholarly impact.

Education 🎓

Dr. Kung earned her Ph.D. in Biological Science from National Sun Yat-sen University, Kaohsiung, Taiwan, in 2012, under the guidance of Prof. Tai Ming-Hong. Her dissertation focused on the mechanisms of hepatoma-derived growth factor-mediated cell migration and epithelial-mesenchymal transition. She also holds an M.S. in Biochemistry from Kaohsiung Medical University (2002) and a B.S. in Nutrition from Chung Shan Medical University (2000).

Experience 🌟

Dr. Kung has extensive experience in academia and research. Since 2019, she has been a Senior Assistant Research Fellow at Kaohsiung Veterans General Hospital. She also holds a faculty position at Shu-Zen Junior College of Medicine and Management. Previously, she served as an Assistant Faculty member (2017-2019) and a Postdoctoral Research Associate (2012-2017) in the Chemistry Department of National Sun Yat-sen University, working under Dr. Shuchen Hsieh.

Research Interests On Pharmacology 📚

Dr. Kung’s research interests include cancer biology, gene engineering, phytochemical pharmacology, and toxicology. She is particularly focused on the development and applications of green nanomaterials for cancer treatment. Her work explores novel phytochemically derived nanoparticles and their effects on cancer cell adhesion, proliferation, and metastasis.

Awards 🏆

  • 2021: Taiwan Urology Association “Best Academic Activity Award – Best Poster Award”
  • 2018: National Taiwan University System Young Scholars Selection for Innovative Research and Development Achievements – Excellent Work Award
  • 2015: New Advance in Generation Medicine, Cancer and Stem Cell Outstanding Paper Award
  • 2013: IEEE Nanotechnology Materials and Devices Conference, Outstanding Paper Award

Publications 📰

Dr. Kung has authored numerous peer-reviewed publications in high-impact journals. Below are some of her notable works:

  1. Wang, J.-H., Chen, Y.-W., Hsieh, S., & Kung, M.-L.* (2025). “Nanosized ginger-derived phenolic zingerone obstructs cell cycle G2/M progression and initiates apoptosis in human colorectal cancer.” Environmental Toxicology. DOI:10.1002/tox.24470 (SCI; 2023 IF=4.4)
  2. Chu, L.-W., Chen, J.-Y., Chen, Y.-W., Hsieh, S., & Kung, M.-L.* (2024). “Phytoconstituent-derived zingerone nanoparticles disrupt cell adhesion and suppress cell motility in melanoma B16F10 cells.” Journal of Biotechnology. DOI:10.1016/j.jbiotec.2024.06.015
  3. Kung, M.-L., Cheng, S. M., Wang, Y.-H., et al.* (2024). “Deficiency of RNA adenosine deaminase (ADAR2) ameliorates metabolic-associated fatty liver disease via AMPK signaling pathways in male diet-induced obese mice.” Communications Biology. (SCI; 2022 IF=5.9)
  4. Kung, M.-L., Yang, T.-H., Lin, C.-C., et al.* (2024). “ADAR2 deficiency ameliorates nonalcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1.” Journal of Cachexia, Sarcopenia and Muscle. DOI:10.1002/jcsm.13460 (SCI; 2022 IF=8.9)
  5. Hu, T.-H., Wu, J.-C., Huang, S.-T., et al.* (2023). “HDGF Stimulates Liver Tumorigenesis by Enhancing Reactive Oxygen Species Generation in Mitochondria.” Journal of Biological Chemistry. (SCI; 2022 IF=4.8)

Conclusion 📚

Dr. Mei-Lang Kung has made remarkable contributions to cancer research and nanomedicine, with a strong emphasis on translating scientific discoveries into therapeutic applications. Her expertise in molecular oncology and green nanotechnology continues to impact the scientific community, making her a leader in the field of biomedical research. Through her innovative work, she strives to advance cancer treatment strategies and improve patient outcomes.